author-photo

Libo Sun

Geron Corporation

10

Papers

44

Citations

Citation Trend

Filter By

Papers (6) Sort By

Journal Conference Others

IMerge: A phase 3 study to evaluate imetelstat in transfusion-dependent subjects with IPSS low or intermediate-1 risk myelodysplastic syndromes that are relapsed/refractory to erythropoiesis-stimulating agent treatment.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Treatment with Imetelstat Improves Myelofibrosis-Related Symptoms and Other Patient-Reported Outcomes in Patients with Relapsed or Refractory Higher-Risk Myelofibrosis

2020 Blood
Show All
- Source
- Cite
- Save
Citations (1)
Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusion-Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II Study.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (19)
A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-Risk Myelofibrosis (MF) Refractory to Janus Kinase (JAK) Inhibitor

2020 Blood
Show All
- Source
- Cite
- Save
Citations (8)
Potential Disease-Modifying Activity of Imetelstat Demonstrated By Reduction in Cytogenetically Abnormal Clones and Mutation Burden Leads to Clinical Benefits in Relapsed/Refractory Myelofibrosis Patients

2020 Blood
Show All
- Source
- Cite
- Save
Citations (5)
Imerge: A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) That Is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

2019 Blood
Show All
- Source
- Cite
- Save
Citations (3)